Astrazeneca (AZN) Raw Materials (2015 - 2025)

Astrazeneca's Raw Materials history runs 11 years deep, the most recent figure standing at $1.9 billion for Q4 2025.

• In Q4 2025, Raw Materials rose 24.71% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (up 24.71% YoY), while the FY2025 annual figure was $1.9 billion, up 24.71% from the prior year.
• Raw Materials was $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $1.9 billion in Q4 2025 to a low of $1.4 billion in Q4 2022.
• Historically, Raw Materials has averaged $1.6 billion across 5 years, with a median of $1.5 billion in 2023.
• The sharpest annual moves came in 2021 and 2022: Raw Materials soared 39.06% in 2021, then fell 18.97% in 2022.
• A 5-year view of Raw Materials shows it stood at $1.8 billion in 2021, then dropped by 18.97% to $1.4 billion in 2022, then rose by 7.67% to $1.5 billion in 2023, then dropped by 2.74% to $1.5 billion in 2024, then advanced by 24.71% to $1.9 billion in 2025.
• The last three Raw Materials figures came in at $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.5 billion (Q4 2023), per Business Quant data.